


## Nemifitide diTFA

<b>Cat. No.:</b>	HY-105077A
<b>CAS No.:</b>	204992-09-6
<b>Molecular Formula:</b>	C <sub>37</sub> H <sub>45</sub> F <sub>7</sub> N <sub>10</sub> O <sub>10</sub>
<b>Molecular Weight:</b>	922.8
<b>Sequence:</b>	{Fluoro-Phe}-{Hyp}-Arg-Gly-Trp-NH <sub>2</sub>
<b>Sequence Shortening:</b>	{Fluoro-Phe}-{Hyp}-RGW-NH <sub>2</sub>
<b>Target:</b>	5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Sealed storage, away from moisture and light
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 250 mg/mL (270.91 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		1.0837 mL	5.4183 mL	10.8366 mL
	5 mM		0.2167 mL	1.0837 mL	2.1673 mL
	10 mM		0.1084 mL	0.5418 mL	1.0837 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Nemifitide diTFA (INN 00835 diTFA) is a synthetic pentapeptide antidepressant with a potential for rapid onset of action<sup>[1]</sup>. Nemifitide diTFA is a peptide analog of melanocyte-inhibiting factor (MIF)<sup>[2]</sup>. Nemifitide diTFA can cross the blood-brain barrier<sup>[3]</sup>.

#### In Vitro

Nemifitide diTFA (INN 00835 diTFA) and its active metabolite (M1) bind at micromolar concentrations to several receptors including the 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, melanocortin MC4, MC5 and bombesin<sup>[3]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Nemifitide diTFA (INN 00835 diTFA; 0.3 mg/kg; IP; daily; for 14 days) significantly increases swimming in the FSL rats after just 5 days of treatment and has long-lasting effect<sup>[2]</sup>.  
Nemifitide diTFA (0.0125-15.0 mg/kg) significantly increases swimming in the FSL rats at both low (0.025-0.3 mg/kg) and high

(3.0-15.0 mg/kg) doses but not at intermediate (0.4-2.4 mg/kg) doses<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Flinders Sensitive Line (FSL) rat weighing 280-320 g <sup>[2]</sup>
Dosage:	0.3 mg/kg
Administration:	IP; daily; for 14 days
Result:	Significantly increased swimming in the FSL rats after just 5 days of treatment and had long-lasting effect.

## REFERENCES

- [1]. Kelly JP, et al. The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients. *J Affect Disord.* 1999 Oct;55(2-3):231-5.
- [2]. Overstreet DH, et al. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. *Psychopharmacology (Berl).* 2004 Sep;175(3):303-9.
- [3]. Montgomery SA, et al. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. *Int J Neuropsychopharmacol.* 2006 Oct;9(5):517-28.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA